10x Genomics has delivered a very strong share price run, and the question now is whether the current valuation can be supported by its sales. With that kind of move already in the rear-view mirror, you need to know if the revenue base is enough to justify where the stock trades today.
-
The stock is up about 4.8x over the past year, which puts real pressure on the case that its sales can carry this higher price tag.
-
The business model relies on selling instruments and consumables into research labs, which can support recurring revenue but also ties valuation expectations closely to the pace and durability of future product demand.
-
There is a second opinion on 10x Genomics worth weighing. See what analysts think 10x Genomics's shares could be worth .
The issue now is whether 10x Genomics' current share price can be explained by its sales when compared with the Fair Ratio benchmark.
If you want a reality check on 10x Genomics' 484.9% one year return, compare it with companies in the same phase of the journey using our screener containing 21 high quality undiscovered gems .
Has 10x Genomics Run Too Far on Sales?
P/S is the cleaner yardstick for 10x Genomics because the focus is on how much investors are paying for its revenue base rather than its current earnings. The stock trades on a P/S of 16.5x, which is more than triple the Life Sciences industry average of 4.9x and well above the peer group at 6.0x. That already tells you the market is attaching a steep price tag to every dollar of 10x Genomics revenue.
The Fair Ratio, which reflects what might be expected given 10x Genomics' size, sector, quality profile and risk, sits below the current 16.5x P/S. That gap points to the shares screening as overvalued on this framework rather than merely rich compared with a simple sector average. For anyone looking at NasdaqGS:TXG, the key question is whether the underlying business can sustain the kind of revenue performance that would justify paying such a premium multiple today. Explore the numbers behind 10x Genomics's P/S valuation .
The 10x Genomics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the 10x Genomics valuation puzzle leaves off by explaining which future assumptions on growth, margins and earnings would need to hold for the stock to be worth far more or considerably less than it is today. Each narrative treats 10x Genomics' fair value as a thesis about the business that can be tracked over time, rather than a one-off snapshot, and they sit on Simply Wall St's Community page.
Community views on 10x Genomics are split between those who see extra upside in the product pipeline and those who think most of that story is already reflected in the price.
Bull case: 29% undervalued
"Sentira extends 10x Genomics from instruments and consumables into paid cloud analysis, with a paid product in early 2027 creating a new recurring software revenue line..."
Discover why this Narrative puts 10x Genomics at 29% undervalued .
Bear case: roughly fairly valued
"Product transitions to lower-cost solutions, while driving higher reaction volumes, are creating a near-term headwind to consumables revenue growth, as price declines are not yet fully offset by increased volume..."
Explore why this Narrative puts 10x Genomics at roughly fairly valued .
The 10x Genomics story is not complete if you only look at the share price
There is one more piece you should check before forming a view on 10x Genomics, because our broader review has highlighted specific cautions that deserve a closer look. Take a closer look at 3 warning signs before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TXG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
